Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Citius Pharmaceuticals Inc (NQ: CTXR )

0.3922 +0.0038 (+0.98%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Citius Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm
Via Benzinga
Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial
Via Benzinga
Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 52.5% to $0.7050 in pre-market trading after jumping over 72% on Friday. 
Via Benzinga
Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+... 
Via Benzinga
Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) rose 41.5% to $0.3255 in pre-market trading after gaining 8% on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket
Gainers 
Via Benzinga
11 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million. 
Via Benzinga
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
Via Benzinga
Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
3 Reddit Stocks to Buy in May
These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond 
Via InvestorPlace
The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
Via Viz Release
Exposures COVID-19 Product Safety
61 Biggest Movers From Yesterday
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with... 
Via Benzinga
First Patient Dosed in Citius Pharma's Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced enrolment of first patient in the Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Healthcare Triangle (NASDAQ:HCTI) stock moved upwards by 17.5% to $1.35 during Wednesday's pre-market session. The company's market cap stands at $47.6... 
Via Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Rhythm Pharmaceuticals (NASDAQ:RYTM) stock increased by 16.4% to $7.72 during Thursday's regular session. The current volume of 639.5K shares is 152.7% of... 
Via Benzinga
Penny Stock Watchlist - Here Are My Five Top Picks
If you got into Amazon at the start of 2021, by the end of 2021 you'd have made about 73% gains. Not bad for a year. It's impressive until you consider that one of these stocks made 258% gains in the... 
Via Talk Markets
FDA Signs Off Citius Pharma's Phase 2 Trial With Halo-Lido In Hemorrhoids
The FDA has issued a Study May Proceed letter for Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Halo-Lido to treat hemorrhoids. The Company anticipates... 
Via Benzinga
Citius Pharmaceuticals: Q1 Earnings Insights
Citius Pharmaceuticals (NASDAQ:CTXR) reported its Q1 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Citius... 
Via Benzinga
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ: 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.